US psychiatrists’ views on prescribing Otsuka/Lundbeck’s brexpiprazole
Surveyed US psychiatrists are receptive to novel adjunctive therapies to antidepressants for treatment-resistant depression (TRD) and would prescribe Japanese drugmaker Otsuka (TYO: 4768) and Danish CNS specialist Lundbeck’s (LUND: CO) emerging atypical antipsychotic brexpiprazole to a mean 12% of their drug-treated TRD patients in 2015.
According to new research from Decision Resources Group, this value is slightly lower than the 16% patient share surveyed psychiatrists currently estimate for Bristol-Myers Squibb (NYSE: BMY)/Otsuka’s Abilify (aripiprazole). Additionally, nearly one-third of surveyed psychiatrists willing to prescribe brexpiprazole would be most compelled to switch their TRD patients from adjunctive treatment with Abilify if brexpiprazole offered a lower risk of restlessness and/or akathisia (restless movements, inner restlessness and distress) compared to Abilify.
Other key findings from the Physician and Payer Forum report include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze